Lenalidomide in Diffuse Large B-Cell Lymphoma
Joint Authors
Coiffier, Bertrand
Delfau-Larue, Marie-Hélène
Thieblemont, Catherine
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-11-20
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma (NHL) in adults.
Even if the natural history of DLBCL has been improved with the advent of immunochemotherapy, the survival results obtained with current treatment options clearly indicate that new agents or novel approaches are needed.
Lenalidomide (Revlimid, Celgene Corporation, Summit, NJ, USA), an analogue of thalidomide, is an immunomodulatory drug with pleiotropic mechanisms of action potentially adding to immunochemotherapy.
We present here the biological rational for the use of lenalidomide in DLBCL in light of recent advances in the pathophysiology of the disease and the therapeutic results of the most recent trials published in literature or reported in meetings in relapsed/refractory situations as well as in first-line treatment.
American Psychological Association (APA)
Thieblemont, Catherine& Delfau-Larue, Marie-Hélène& Coiffier, Bertrand. 2012. Lenalidomide in Diffuse Large B-Cell Lymphoma. Advances in Hematology،Vol. 2012, no. 2012, pp.1-8.
https://search.emarefa.net/detail/BIM-504148
Modern Language Association (MLA)
Thieblemont, Catherine…[et al.]. Lenalidomide in Diffuse Large B-Cell Lymphoma. Advances in Hematology No. 2012 (2012), pp.1-8.
https://search.emarefa.net/detail/BIM-504148
American Medical Association (AMA)
Thieblemont, Catherine& Delfau-Larue, Marie-Hélène& Coiffier, Bertrand. Lenalidomide in Diffuse Large B-Cell Lymphoma. Advances in Hematology. 2012. Vol. 2012, no. 2012, pp.1-8.
https://search.emarefa.net/detail/BIM-504148
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-504148